ClinicalTrials.Veeva

Menu
A

Adams Clinical Watertown

Research site

Site insights

Top conditions

Top treatments

Brenipatide
Rapastinel
SPD489
Seltorexant
Donanemab
LY3002813
SEP-363856
Dasotraline
Esketamine
CYB003

Parent organization

This site is a part of Adams Clinical

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Clinical Trial Outreach Team

Verified by this site

Active trials

27 of 79 total trials

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (TRONTIER 2)

The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild c...

Active, not recruiting
Alzheimers Disease
Drug: Trontinemab
Other: Placebo

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized A...

Active, not recruiting
Generalized Anxiety Disorder
Drug: DT120
Other: Placebo

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depress...

Active, not recruiting
Major Depressive Disorder
Other: Placebo
Drug: DT120

X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of...

Active, not recruiting
Major Depressive Disorder
Drug: Azetukalner
Drug: Placebo

The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in pat...

Enrolling
Depression in Adults
Depression Disorders
Drug: CYB003
Behavioral: Psychological Support

This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying th...

Enrolling
Depressive Disorder, Major
Drug: Placebo
Drug: Brenipatide

The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC), compared with placebo pl...

Enrolling
Bipolar Disorder
Drug: Brenipatide
Drug: Placebo

This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying th...

Enrolling
Depressive Disorder, Major
Drug: Placebo
Drug: Brenipatide

The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus...

Enrolling
Schizophrenia
Drug: Placebo
Drug: Brenipatide

This study evaluates the safety and efficacy of brenipatide (LY3537031) as an add on therapy in participants with major depression who still have sym...

Not yet enrolling
Major Depressive Disorder
Drug: Brenipatide
Drug: Placebo

The purpose of this study is to see if brenipatide, when compared to placebo, is safe and effective for participants with opioid use disorder, when u...

Enrolling
Opioid Use Disorder
Drug: Brenipatide
Drug: Buprenorphine

This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptom...

Active, not recruiting
Alzheimer's Disease
Mental Disorders
Drug: Placebo
Drug: Donanemab

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The purpose of this study is to evaluate how well each individual dose of esketamine (56 milligrams \[mg\] and 84 mg) works when compared with placeb...

Enrolling
Depressive Disorder, Treatment-Resistant
Drug: Placebo
Drug: Esketamine 84 mg

The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's...

Active, not recruiting
Alzheimer's Disease
Drug: Placebo
Drug: Remternetug

The main purpose of this study is to assess how well the study drug (JNJ-42847922) works (efficacy) compared with placebo in improving depressive sym...

Enrolling
Depressive Disorder, Major
Drug: Placebo
Drug: Seltorexant

This study will evaluate the efficacy and safety of trontinemab in participants with biomarker evidence of Alzheimer's Disease (AD) pathology but wit...

Enrolling
Alzheimer's Disease
Drug: Placebo
Drug: Trontinemab

The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to...

Enrolling
Alzheimer Disease
Drug: Zunveyl®

Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Cli...

Enrolling
Alzheimer's Disease
Drug: ABBV-1758
Drug: Placebo for ABBV-1758

The primary purpose of this study is to evaluate the efficacy of centanafadine once daily (QD) extended-release (XR) capsules in adults with attentio...

Enrolling
Attention-deficit/Hyperactivity Disorder
Emotional Dysregulation
Drug: Centanafadine XR

Trial sponsors

Lilly logo
Janssen (J&J Innovative Medicine) logo
Otsuka logo
Allergan logo
Indivior logo
Shire logo
A
Acadia Pharmaceuticals logo
Forest Laboratories logo
Roche logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems